Your browser doesn't support javascript.
loading
Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
Ubink, I; Bloemendal, H J; Elias, S G; Brink, M A; Schwartz, M P; Holierhoek, Y C W; Verheijen, P M; Boerman, A W; Mathijssen, R H J; de Leng, W W J; de Weger, R A; van Grevenstein, W M U; Koopman, M; Lolkema, M P; Kranenburg, O; Borel Rinkes, I H M.
Affiliation
  • Ubink I; Department of Surgical Oncology, Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • Bloemendal HJ; Department of Medical Oncology, Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • Elias SG; Department of Medical Oncology, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • Brink MA; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584CG, Utrecht, The Netherlands.
  • Schwartz MP; Department of Gastroenterology, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • Holierhoek YCW; Department of Gastroenterology, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • Verheijen PM; Department of Gastroenterology, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • Boerman AW; Department of Surgery, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • Mathijssen RHJ; Department of Medical Oncology, Meander Medical Center, Maatweg 3, 3813TZ, Amersfoort, the Netherlands.
  • de Leng WWJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands.
  • de Weger RA; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • van Grevenstein WMU; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • Koopman M; Department of Surgical Oncology, Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • Lolkema MP; Department of Medical Oncology, Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands.
  • Kranenburg O; Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, 3015CE, Rotterdam, the Netherlands.
  • Borel Rinkes IHM; Department of Surgical Oncology, Cancer Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX, Utrecht, The Netherlands. o.kranenburg@umcutrecht.nl.
BMC Cancer ; 17(1): 282, 2017 04 19.
Article de En | MEDLINE | ID: mdl-28424071
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs colorectales / Mésilate d'imatinib / Antinéoplasiques Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article Pays d'affiliation: Pays-Bas Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs colorectales / Mésilate d'imatinib / Antinéoplasiques Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article Pays d'affiliation: Pays-Bas Pays de publication: Royaume-Uni